Card14gene (rs34367357 ) Polymorphism in Egyptian Psoriatic and Psoriatic Arthritis Patient and Its Relation With Response to Methotrexate

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Psoriasis is a chronic, immune-mediated, multisystemic, inflammatory disease caused by the interaction of multiple susceptibility genes and environmental factors that affects 1-3% of the population worldwide .Psoriasis also is a chronic inflammatory skin disease characterized by scaly indurated erythema. Psoriatic arthritis (PsA) is an autoimmune and chronic musculoskeletal disorder that is associated with psoriasis of the skin . Its presentation can vary from subtle manifestations to highly destructive forms. Joint pain, stiffness and swelling are the most common symptoms.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 50
Healthy Volunteers: f
View:

• Patients aged 18 years and above.

• Patients having psoriasis diagnosed clinically and who have a severity grade of moderate to severe, defined as a Psoriasis Area and Severity Index (PASI) score from 5- 10 % of body surface area, and involvement of greater than 10% of the body surface area (BSA) with or without psoriatic arthritis

Locations
Other Locations
Egypt
Qina University hospital, South Valley University Hospital
RECRUITING
Qina
Contact Information
Primary
Marwa Naguib Ahmed, MSc
omarahmed331166@yahoo.com
+201099283315
Backup
Soheir Abdel-Hamid Ali
Soher.abdel-hamed@med.svu.edu.eg
+201066877343
Time Frame
Start Date: 2025-03-05
Estimated Completion Date: 2026-03-10
Participants
Target number of participants: 50
Treatments
Active_comparator: Group A
About 20 patients with psoriasis
Active_comparator: Group B
About 20 psoriatic arthritis
Placebo_comparator: Group C
About 10 healthy control group
Related Therapeutic Areas
Sponsors
Leads: South Valley University

This content was sourced from clinicaltrials.gov